Afdhal, Nezam H.

Liver cirrhosis

Schuppan, D., & Afdhal, N. H. (2008) · The Lancet

Liver Disease and TransplantationLiver physiology and pathology

Cited by 2,089

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study

Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet

Hepatitis B Virus StudiesHepatitis C virus research

Cited by 1,788

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 549

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 390

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Harrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 384

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W., Romero‐Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., et al. (2019) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 277

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib

Jayakumar, S., Middleton, M. S., Lawitz, E. J., Mantry, P. S., Caldwell, S. H., Arnold, H., Mae Diehl, A., Ghalib, R., Elkhashab, M., Abdelmalek, M. F., et al. (2019) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography

Cited by 208

Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease

Muir, A. J., Levy, C., Janssen, H. L. A., Montano‐Loza, A. J., Shiffman, M. L., Caldwell, S., Luketic, V., Ding, D., Jia, C., McColgan, B. J., et al. (2019) · Hepatology

Liver Diseases and ImmunityLiver physiology and pathology

Cited by 195

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 171

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 110

Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score

Tapper, E. B., Hunink, M. G. M., Afdhal, N. H., Lai, M., & Sengupta, N. (2016) · PLoS ONE

Liver Disease Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 68